IN2015DN03132A - - Google Patents

Info

Publication number
IN2015DN03132A
IN2015DN03132A IN3132DEN2015A IN2015DN03132A IN 2015DN03132 A IN2015DN03132 A IN 2015DN03132A IN 3132DEN2015 A IN3132DEN2015 A IN 3132DEN2015A IN 2015DN03132 A IN2015DN03132 A IN 2015DN03132A
Authority
IN
India
Prior art keywords
present
provides various
oral delivery
various formulations
angiotensin peptides
Prior art date
Application number
Inventor
Richard Franklin
William Stern
Austin Vryhof
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of IN2015DN03132A publication Critical patent/IN2015DN03132A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The present invention provides various formulations for oral delivery of angiotensin peptides.
IN3132DEN2015 2012-09-17 2013-09-17 IN2015DN03132A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261701972P 2012-09-17 2012-09-17
PCT/US2013/060139 WO2014043693A1 (en) 2012-09-17 2013-09-17 Oral formulations of angiotensin

Publications (1)

Publication Number Publication Date
IN2015DN03132A true IN2015DN03132A (en) 2015-10-02

Family

ID=50278763

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3132DEN2015 IN2015DN03132A (en) 2012-09-17 2013-09-17

Country Status (13)

Country Link
US (1) US20150246093A1 (en)
EP (1) EP2895154A4 (en)
JP (1) JP2015529684A (en)
KR (1) KR20150065736A (en)
CN (1) CN104853749A (en)
AU (1) AU2013315004A1 (en)
BR (1) BR112015005738A2 (en)
CA (1) CA2884792A1 (en)
HK (1) HK1213785A1 (en)
IN (1) IN2015DN03132A (en)
MX (1) MX2015003407A (en)
RU (1) RU2015108678A (en)
WO (1) WO2014043693A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102294577B1 (en) * 2015-01-12 2021-08-26 엔터리스 바이오파마, 인크. solid oral dosage form
US10829519B2 (en) 2015-09-18 2020-11-10 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
WO2023063376A1 (en) * 2021-10-13 2023-04-20 中外製薬株式会社 Composition including peptide compound and surfactant
WO2023214509A1 (en) * 2022-05-02 2023-11-09 中外製薬株式会社 Composition containing peptide compound for use with surfactant
WO2024080308A1 (en) * 2022-10-12 2024-04-18 中外製薬株式会社 Composition containing peptide, surfactant, and polymer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
US20080199434A1 (en) * 2006-11-13 2008-08-21 Board Of Trustees Of The University Of Arkansas Compositions and methods for the treatment of cardiovascular conditions
US8377863B2 (en) * 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
BRPI0800585B8 (en) * 2008-02-13 2021-05-25 Univ Minas Gerais pharmaceutical compositions of des-[asp1]-[ala1]-angiotensin-(1-7) peptide and use of des-[asp1]-[ala1]-angiotensin-(1-7) peptide
ES2393455T3 (en) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Use of an Ang- (1-7) receptor agonist in acute lung lesions
CN105581984A (en) * 2009-04-09 2016-05-18 阿尔科米斯制药爱尔兰有限公司 Drug delivery composition
KR101514414B1 (en) * 2011-02-02 2015-05-04 유니버시티 오브 써던 캘리포니아 Methods for treating diabetic foot ulcers

Also Published As

Publication number Publication date
MX2015003407A (en) 2015-10-14
WO2014043693A1 (en) 2014-03-20
EP2895154A4 (en) 2016-04-20
EP2895154A1 (en) 2015-07-22
RU2015108678A (en) 2016-11-10
HK1213785A1 (en) 2016-07-15
JP2015529684A (en) 2015-10-08
CA2884792A1 (en) 2014-03-20
US20150246093A1 (en) 2015-09-03
AU2013315004A1 (en) 2015-04-02
BR112015005738A2 (en) 2017-08-08
CN104853749A (en) 2015-08-19
KR20150065736A (en) 2015-06-15

Similar Documents

Publication Publication Date Title
MX2019013123A (en) Oral dosing of glp-1 compounds.
JO3755B1 (en) Testosterone formulations
MX2013015311A (en) Pcsk9-binding polypeptides and methods of use.
IN2015DN00127A (en)
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MY172292A (en) Vectors and sequences for the treatment of diseases
AU2013337247A8 (en) XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
HK1221654A1 (en) Compositions, methods & systems for respiratory delivery of three or more active agents
MY168300A (en) Pharmaceutical Composition for Inhalation
TN2014000136A1 (en) Selective androgen receptor modulators
IN2014DN09450A (en)
HK1216720A1 (en) Bioerodible silicon-based compositions for delivery of therapeutic agents
IN2015DN03132A (en)
HK1208188A1 (en) Formulations for the delivery of active ingredients
IN2014CN00312A (en)
MY165088A (en) Pharmaceutical compositions comprising alisporivir
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
IN2014DN10209A (en)
GB2509470A (en) Pharmaceutical compositions of antihypertensives
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
MX2015001134A (en) Therapeutic compounds.
IN2013CH05395A (en)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA72478U (en) Use of polentar as frigoprotector
IN2012DE01204A (en) "shikhar technology"